½ÃÀ庸°í¼­
»óǰÄÚµå
1405908

¹Ì±¹ ¹× ÀϺ»ÀÇ ´ÙÇ÷¼ÒÆÇ Ç÷Àå ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼­ : À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, ±¹°¡º°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

U.S. And Japan Platelet Rich Plasma Market Size, Share & Trends Analysis Report By Type, (Pure Platelet Rich Plasma, Leukocyte Rich Platelet Rich Plasma), By Application, By End-use, By Country, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 125 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹Ì±¹ ¹× ÀϺ»ÀÇ ´ÙÇ÷¼ÒÆÇ Ç÷Àå ½ÃÀå ¼ºÀå ¹× µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¹Ì±¹°ú ÀϺ»ÀÇ ´ÙÇ÷¼ÒÆÇ Ç÷Àå ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2030³â±îÁö 10.15%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³»°í, 2030³â±îÁö 3¾ï 4,845¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÈ´Ù°í ÇÕ´Ï´Ù.

¹Ì±¹ ¹× ÀϺ»ÀÇ ´ÙÇ÷¼ÒÆÇ Ç÷Àå(PRP) ½ÃÀåÀº Á¤Çü¿Ü°ú Áúȯ ¹× ½ºÆ÷Ã÷ ºÎ»ó ¹ß»ý·ü Áõ°¡, ¹Ì¿ë ¼ö¼ú Áõ°¡, ´ÙÇ÷¼ÒÆÇ Ç÷ÀåÀÇ ÀÇ·á¿ëµµ È®´ë¿¡ ÈûÀÔ¾î ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´ÙÇ÷¼ÒÆÇ Ç÷ÀåÀ» ÀÌ¿ëÇÑ »óó Ä¡À¯¿¡ ´ëÇÑ Áõ°Å ±â¹Ý ¿¬±¸ Áõ°¡´Â Àüü ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

±Ù°ñ°Ý°è Áúȯ, Á¤Çü¿Ü°ú Áúȯ ¹× ½ºÆ÷Ã÷ ºÎ»ó Ä¡·á¿¡ ´ÙÇ÷¼ÒÆÇ Ç÷Àå Á¦Ç°ÀÇ Àû¿ëÀº ÃÖ±Ù ¸î ³âµ¿¾È ´õ ³Î¸® º¸±ÞµÇ¾úÀ¸¸ç, ¿©·¯ ¿¬±¸¿¡¼­ PRPÀÇ ¼ºÀå ÀÎÀÚ ³óµµ¸¦ ³ôÀ̸é Ä¡À¯ °úÁ¤À» ÃËÁøÇÒ ¼ö ÀÖ´Ù´Â »ç½ÇÀÌ ¿©·¯ ¿¬±¸¿¡¼­ °üÂûµÇ¾ú½À´Ï´Ù. ÀÌ ºÐ¾ß¿¡¼­ ÀÚ°¡ Á¦Ç°ÀÇ ÁÖ¿ä °ø±Þ¿øÀÌÀÚ Ä¡À¯ °úÁ¤ÀÇ ÁøÁ¤ÇÑ Àü±¸Ã¼ÀÓÀÌ ÀÔÁõµÇ¾ú½À´Ï´Ù. ¹Ì±¹ CDCÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é, ¹Ì±¹ ³» ½ºÆ÷Ã÷ Âü¿©´Â Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼­´Â ¾à 3,000¸¸ ¸íÀÇ ¾î¸°ÀÌ¿Í Ã»¼Ò³âÀÌ ½ºÆ÷Ã÷¿¡ Âü¿©Çϰí ÀÖÀ¸¸ç, ÀþÀº ¼±¼öµé »çÀÌ¿¡¼­ ½ºÆ÷Ã÷ ºÎ»óÀÇ À§ÇèÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ Á¤Çü¿Ü°ú Áúȯ°ú ½ºÆ÷Ã÷ ºÎ»ó ¹ß»ý·ü Áõ°¡´Â ´ÙÇ÷Áú Ç÷Àå Ä¡·á ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌĨ´Ï´Ù.

¹Ì¿ë ¼ö¼ú Áõ°¡´Â ´ÙÇ÷¼ÒÆÇ Ç÷Àå Á¦Ç° ¼ö¿ä¸¦ ÃËÁøÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, ASPS¿¡ µû¸£¸é È­Àåǰ¿¡¼­ PRPÀÇ »ç¿ëÀº Áö³­ 4³âµ¿¾È 25% Áõ°¡Çß½À´Ï´Ù. ¶ÇÇÑ ¹Ì±¹°ú ÀϺ»¿¡¼­´Â ¹Ì¿ë ¼ö¼úÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â Á¶»ç ±â°£ µ¿¾È ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹¾È¸é¼ºÇüÀç°Ç¿Ü°úÇÐȸ(AAFPRS)ÀÇ ¿¬·Ê Á¶»ç¿¡ µû¸£¸é 2018³â ÁÖ»çÁ¦°¡ ¾È¸é¼ºÇü¿Ü°ú ÀÇ»çµéÀÌ °¡Àå ¸¹ÀÌ Ã¤ÅÃÇÑ Ä¡·á ¿É¼ÇÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¹Ì¿ë ¼ö¼ú ¹× ÃÖ¼Ò Ä§½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ ¹Ì±¹ÀÎÀÇ ¸·´ëÇÑ ÁöÃâµµ ´ÙÇ÷Áú Ç÷Àå ½ÃÀåÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, Aesthetic SocietyÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é ¹Ì±¹ÀεéÀº 2022³â ÃÖ¼Ò Ä§½ÀÀû ¼ö¼ú ¹× ¹Ì¿ë ¼ºÇü ¼ö¼ú¿¡ ¾à 118¾ï ´Þ·¯¸¦ ÁöÃâÇÏ¿© Àü³â ´ëºñ 2% Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù.

´ÙÁß Ç÷¼ÒÆÇ Ç÷ÀåÀÇ À¯¿ë¼ºÀº ¹Ì¿ë ¹× ÇǺΰú¿¡¼­ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ½ÃÁß¿¡¼­ ÆÇ¸ÅµÇ´Â ½Ã½ºÅÛÀº Áï½Ã »ç¿ë °¡´ÉÇÑ ¹«±Õ PRP Çöʾ×À» Á¦°øÇÏÁö¸¸, ÀÌ·¯ÇÑ Á¦Ç°°ú °ü·ÃµÈ ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ ÀÇ·á Àü¹®°¡°¡ PRP ŰƮ¸¦ ´ë±Ô¸ð·Î ¹èÆ÷ÇÏ´Â µ¥ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. ´Ù¸¥ Ä¡·á¹ý¿¡ ºñÇØ PRP ÁÖÀÔÀÇ ³ôÀº ºñ¿ëÀº ȯÀÚ¿Í ÀÓ»óÀÇ¿¡°Ô Å« °ü½É»çÀÔ´Ï´Ù. ¶ÇÇÑ, PRP ¿ä¹ýÀ» µÞ¹ÞħÇÏ´Â Áõ°Å°¡ ºÎÁ·Çϱ⠶§¹®¿¡ º¸ÇèÀº ÀÌ·¯ÇÑ Á¦Ç°À» º¸ÀåÇÏÁö ¾Ê½À´Ï´Ù. ¹Ì±¹ Á¤Çü¿Ü°ú ÇÐȸ´Â PRPÀÇ °á°ú´Â Ä¡·á ´É·Â¿¡ µû¶ó ȯÀÚ¸¶´Ù ´Ù¸£´Ù°í ¹àÇû½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ Á¦Ç°°ú °ü·ÃµÈ ºñ¿ëÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀ» ÀúÇØÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

¹Ì±¹ ¹× ÀϺ»ÀÇ ´ÙÇ÷¼ÒÆÇ Ç÷Àå ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ® :

  • À¯Çüº°·Î´Â ¼ø´ÙÇ÷¼ÒÆÇ Ç÷Àå ºÎ¹®ÀÌ ¼ø´ÙÇ÷¼ÒÆÇ Ç÷ÀåÀÇ ÀåÁ¡°ú ´Ù¾çÇÑ Ä¡·á ¿µ¿ª¿¡¼­ÀÇ Àû¿ë È®´ë¿¡ µû¸¥ ¼ø´ÙÇ÷¼ÒÆÇ Ç÷ÀåÀÇ ³ôÀº äÅ÷ü·Î ÀÎÇØ 2023³â 51.24%ÀÇ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù.
  • ¿ëµµº°·Î´Â ±âŸ ºÎ¹®ÀÌ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµ¿¡ µû¶ó º´¿ø ºÎ¹®Àº 2023³â ½ÃÀå¿¡¼­ °¡Àå Å« ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¹Ì¿ë ¸ñÀûÀ¸·Î PRP Ä¡·áÀÇ ¿ì¼± ¼øÀ§°¡ ³ô¾ÆÁö´Â °ÍÀº ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿ä¼ÒÀÔ´Ï´Ù. Ŭ¸®´Ð ºÎ¹®Àº Ŭ¸®´Ð ¼ö Áõ°¡¿Í ÀÇ·á °ü±¤ Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¹Ì±¹ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ´Â °ÍÀº ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø°ú »õ·Î¿î PRP Áغñ ½Ã½ºÅÛ °³¹ß¿¡ ÁÖ·ÂÇÏ´Â ¸¹Àº ´ëÇü Á¦Á¶¾÷üÀÇ ÇöÁö ÁøÃâ µîÀÇ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¹Ì±¹ ¹× ÀϺ»ÀÇ Ç÷¼ÒÆÇdzºÎÇ÷Àå ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ¹Ì±¹ ¹× ÀϺ»ÀÇ Ç÷¼ÒÆÇdzºÎÇ÷Àå ½ÃÀå °èÅë Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • ¾È½Ã¶ó¸®¸¶ÄÏÆ®
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ¹Ì±¹ ¹× ÀϺ»ÀÇ Ç÷¼ÒÆÇdzºÎÇ÷Àå ½ÃÀå ºÐ¼® Åø
    • PorterÀÇ Five Forces ºÐ¼®
    • PESTLE ºÐ¼®
    • ÁÖ¿ä ÀÇ°ß ½ÃÁ¡ ºÐ¼®
    • ½ÃÀå ±âȸ ºÐ¼®
    • ±¸ÀÔÀÚ ÀÎ½Ä Á¶»ç
    • ÁÖ¿ä ÀÇ°ß ½ÃÁ¡ ºÐ¼®

Á¦4Àå ¹Ì±¹ ¹× ÀϺ»ÀÇ Ç÷¼ÒÆÇdzºÎÇ÷Àå ½ÃÀå - À¯Çüº° ºÎ¹® ºÐ¼®, 2018³â-2030³â

  • ¹Ì±¹ ¹× ÀϺ»ÀÇ Ç÷¼ÒÆÇdzºÎÇ÷Àå(Prp) ½ÃÀå : À¯Çü º¯µ¿ ºÐ¼®
    • ¼øPRP
    • ´Ù¹éÇ÷±¸ rp
    • ±âŸ

Á¦5Àå ¹Ì±¹ ¹× ÀϺ»ÀÇ Ç÷¼ÒÆÇdzºÎÇ÷Àå ½ÃÀå - ¿ëµµº° ºÎ¹® ºÐ¼®, 2018³â-2030³â

  • ¹Ì±¹ ¹× ÀϺ»ÀÇ Ç÷¼ÒÆÇdzºÎÇ÷Àå(Prp) ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®
    • Á¤Çü¿Ü°ú
    • ±âŸ

Á¦6Àå ¹Ì±¹ ¹× ÀϺ»ÀÇ Ç÷¼ÒÆÇdzºÎÇ÷Àå ½ÃÀå - ÃÖÁ¾ ¿ëµµº° ºÎ¹® ºÐ¼®, 2018³â-2030³â

  • ¹Ì±¹ ¹× ÀϺ»ÀÇ Ç÷¼ÒÆÇdzºÎÇ÷Àå(Prp) ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
    • º´¿ø
    • Ŭ¸®´Ð
    • ±âŸ

Á¦7Àå ¹Ì±¹ ¹× ÀϺ»ÀÇ Ç÷¼ÒÆÇdzºÎÇ÷Àå(Prp) ½ÃÀå : ±¹ ÃßÁ¤¡¤µ¿Ç⠺м®

  • ¹Ì±¹
    • ÁÖ¿ä ±¹°¡ µ¿Çâ
    • ¹Ì±¹ÀÇ Ç÷¼ÒÆÇdzºÎÇ÷Àå
    • °æÀï ½Ã³ª¸®¿À
    • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
    • »óȯ ½Ã³ª¸®¿À
    • ÀϺ»

Á¦8Àå °æÀï ±¸µµ

  • ±â¾÷ ºÐ·ù
  • Participants'Overview
  • À繫 ½ÇÀû
  • Á¦Ç° º¥Ä¡¸¶Å·
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • Àü·« ¸ÅÇÎ
    • È®´ë
    • Çù¾÷
    • ½ÅÁ¦Ç° ¹ß¸Å
    • Àμö
    • ±âŸ
  • List Of Emerging Companies
    • Johnson & Johnson Services, Inc.
    • Arthrex, Inc.
    • EmCyte Corporation
    • Dr. PRP USA LLC
    • Juventix Regenerative Medical, LLC
    • Terumo Corporation
    • Zimmer Biomet
    • Stryker
    • Apex Biologix
    • Celling Biosciences, Inc.
    • Factor Medical, Inc.
    • CAREstream America
    • Royal Biologics.

Á¦9Àå °á·Ð

LSH 24.01.26

U.S. And Japan Platelet Rich Plasma Market Growth & Trends:

The U.S. and Japan platelet rich plasma market size is anticipated to reach USD 348.45 million by 2030, registering a CAGR of 10.15% from 2024 to 2030, according to a new report by Grand View Research, Inc. The U.S. and Japan platelet rich plasma (PRP) market is driven by increasing incidence of orthopedic disorders and sports injuries, growing number of cosmetic surgeries, and expanding medical application of platelet rich plasma. Moreover, increasing evidence-based studies for platelet rich plasma-based wound healing are further propelling growth of overall the market.

The application of platelet rich plasma products in treatment of musculoskeletal conditions, orthopedic disorders, and sports injuries has become more prevalent over recent years. Several research studies have observed that an increased concentration of growth factors in PRP can potentially accelerate healing process. PRP has proven to be a major source of autologous products in the field and a true precursor for healing process along with stem cells & scaffold. According to U.S. CDC data, participation of individuals in sports in the U.S. is continuously rising. Around 30 million children and adolescents in the U.S. participate in sports, which increases risk of sports injuries among young athletes. Therefore, the rise in incidence of orthopedic disorders and sports injuries positively impacts demand for platelet rich plasma treatment procedures.

An increase in cosmetic surgeries drives demand for platelet rich plasma products. For instance, according to the ASPS, a 25% rise in use of PRP in cosmetics was observed in the past 4 years. Moreover, increasing adoption of cosmetic surgeries in the U.S. and Japan is expected to offer lucrative opportunities for the market during the study period. As per an annual survey of the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), injectables became the most adopted treatment option by facial plastic surgeons in 2018. Large spending by Americans on cosmetic surgeries and minimally invasive procedures also drives platelet rich plasma market. According to the Aesthetic Society data, Americans spent approximately USD 11.8 billion on minimally invasive and cosmetic surgery procedures in 2022, reporting an increase of 2% over previous year.

The utility of platelet rich plasma is gaining popularity in aesthetics and dermatology. The commercially marketed systems provide ready-to-apply sterile PRP suspensions; however, high cost associated with these products makes it difficult for healthcare professionals to deploy PRP kits on a large scale. The higher cost of PRP injection as compared to other treatments is a major concern for patients and clinicians. Moreover, insurance policies do not cover these products due to a lack of supportive evidence for PRP therapies. The American Academy of Orthopedic Surgeons stated that PRP results differ from patient to patient, depending on healing capabilities. Thus, cost associated with these products is likely to impede the market over the forecast period.

U.S. And Japan Platelet Rich Plasma Market Report Highlights:

  • Based on type, the pure platelet rich plasma segment dominated the market with a revenue share of 51.24% in 2023 owing to high adoption of pure platelet rich plasma because of its advantages and expanding applications across various therapeutic areas
  • Based on application, the other segment is expected to grow at fastest CAGR over the forecast period
  • Based on end-use, the hospitals segment held the largest revenue share of the market in 2023. Increasing priority of PRP treatment for aesthetic purposes is a significant factor driving growth of this segment. Clinics segment is expected to grow at fastest CAGR over forecast period owing to rising number of clinics and growing medical tourism
  • U.S. dominated the market owing to factors such as supportive regulatory authorities and local presence of many leading manufacturers that focus on developing novel PRP preparation systems

Table of Contents

Chapter 1 Methodology And Scope

  • 1.1 Market Segmentation
    • 1.1.1 Regional Scope
    • 1.1.2 Market Definitions
    • 1.1.3 Estimates And Forecast Timeline
  • 1.2 Objectives
    • 1.2.1 Objective - 1
    • 1.2.2 Objective - 2
    • 1.2.3 Objective - 3
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 Gvr's Internal Database
    • 1.4.3 Secondary Sources
    • 1.4.4 Primary Research
    • 1.4.5 Details Of Primary Research
  • 1.5 Information Or Data Analysis
    • 1.5.1 Data Analysis Models
  • 1.6 Market Formulation & Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
      • 1.7.1.1 Approach 1: Commodity Flow Approach
      • 1.7.1.2 Approach 2: Country Wise Market Estimation Using Bottom-Up Approach
  • 1.8 List Of Secondary Sources
  • 1.9 List Of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Type And Application Segment Snapshot
  • 2.3 End-Use Segment Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 U.S. And Japan Platelet Rich Plasma Market Variables, Trends, And Scope

  • 3.1 U.S. And Japan Platelet Rich Plasma Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Rise In Incidence Of Orthopedic Disorders And Sports Injuries
      • 3.2.1.2 Increasing Cosmetic Surgeries
      • 3.2.1.3 Expanding Medical Applications Of Prp
      • 3.2.1.4 Increasing Evidence-Based Studies For Prp-Based Wound Healing
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 High Costs Associated With Prp Products
  • 3.3 U.S. And Japan Platelet Rich Plasma Market Analysis Tools
    • 3.3.1 Porter's Five Forces Analysis
    • 3.3.2 Pestle Analysis
    • 3.3.3 Key Opinion Perspective Analysis
    • 3.3.4 Market Opportunity Analysis
    • 3.3.5 Buyer Perception Studies
    • 3.3.6 Key Opinion Perspective Analysis

Chapter 4 U.S. And Japan Platelet Rich Plasma Market - Segment Analysis, By Type, 2018 - 2030 (USD Million)

  • 4.1 U.S. And Japan Platelet Rich Plasma (Prp) Market: Type Movement Analysis
    • 4.1.1 Pure Prp
      • 4.1.1.1 Orthopedics
      • 4.1.1.1.1 Sports Medicine
      • 4.1.1.1.2 Spine
      • 4.1.1.1.3 Trauma
      • 4.1.1.1.4 Foot And Ankle
      • 4.1.1.1.5 Joint Reconstruction
    • 4.1.2 Leukocyte-Rich Rich Prp
      • 4.1.2.1 Orthopedics
      • 4.1.2.1.1 Sports Medicine
      • 4.1.2.1.2 Spine
      • 4.1.2.1.3 Trauma
      • 4.1.2.1.4 Foot And Ankle
      • 4.1.2.1.5 Joint Reconstruction
    • 4.1.3 Others
      • 4.1.3.1 Orthopedics
      • 4.1.3.1.1 Sports Medicine
      • 4.1.3.1.2 Spine
      • 4.1.3.1.3 Trauma
      • 4.1.3.1.4 Foot And Ankle
      • 4.1.3.1.5 Joint Reconstruction

Chapter 5 U.S. And Japan Platelet Rich Plasma Market - Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 5.1 U.S. And Japan Platelet Rich Plasma (Prp) Market: Application Movement Analysis
    • 5.1.1 Orthopedics
      • 5.1.1.1 Sports Medicine
      • 5.1.1.2 Spine
      • 5.1.1.3 Trauma
      • 5.1.1.4 Foot And Ankle
      • 5.1.1.5 Joint Reconstruction
    • 5.1.2 Others

Chapter 6 U.S. And Japan Platelet Rich Plasma Market - Segment Analysis, By End Use, 2018 - 2030 (USD Million)

  • 6.1 U.S. And Japan Platelet Rich Plasma (Prp) Market: End-Use Movement Analysis
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Others

Chapter 7 U.S. And Japan Platelet Rich Plasma (Prp) Market: Country Estimates And Trend Analysis

  • 7.1. U.S.
    • 7.1.1 Key Country Dynamics
    • 7.1.2 U.S. Platelet Rich Plasma (Prp) Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.1.3 Competitive Scenario
    • 7.1.4 Regulatory Framework
    • 7.1.5 Reimbursement Scenario
    • 7.1.6 Japan
      • 7.1.6.1 Key Country Dynamics
      • 7.1.6.2 Japan Platelet Rich Plasma (Prp) Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.1.6.3 Competitive Scenario
      • 7.1.6.4 Regulatory Framework
      • 7.1.6.5 Reimbursement Scenario

Chapter 8 Competitive Landscape

  • 8.1 Company Categorization
  • 8.2 Participants' Overview
  • 8.3 Financial Performance
  • 8.4 Product Benchmarking
  • 8.5 Company Market Share Analysis, 2023
  • 8.6 Strategy Mapping
    • 8.6.1 Expansion
    • 8.6.2 Collaborations
    • 8.6.3 New Product Launches
    • 8.6.4 Acquisitions
    • 8.6.5 Others
  • 8.7 List Of Emerging Companies
    • 8.7.1 Johnson & Johnson Services, Inc.
    • 8.7.2 Arthrex, Inc.
    • 8.7.3 EmCyte Corporation
    • 8.7.4 Dr. PRP USA LLC
    • 8.7.5 Juventix Regenerative Medical, LLC
    • 8.7.6 Terumo Corporation
    • 8.7.7 Zimmer Biomet
    • 8.7.8 Stryker
    • 8.7.9 Apex Biologix
    • 8.7.10 Celling Biosciences, Inc.
    • 8.7.11 Factor Medical, Inc.
    • 8.7.12 CAREstream America
    • 8.7.13 Royal Biologics.

Chapter 9 Conclusion

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦